

WBC2020 - Late Breaking

Biomaterials for tissue engineering applications

WBC2020-LATE-4206

Glycerylphytate-crosslinked chitosan lactate microgels as MSC-delivery platform improve cell survival and upregulate secretory profile

Ana Mora-Boza^{*1,2}, Lina M. Mancipe Castro^{3,4}, Rebecca S. Schneider⁵, Woojin M. Han³, Julio San Román^{1,2}, Blanca Vázquez-Lasa^{1,2}, Andrés J. García^{3,4}


¹Institute of Polymer Science and Technology, Spanish National Research Council, ²CIBER-BBN, Health Institute Carlos III, Madrid, Spain, ³Woodruff School of Mechanical Engineering, ⁴Petit Institute for Bioengineering and Bioscience, ⁵School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, United States

Introduction: Mesenchymal stem cells (MSCs) exhibit multiple beneficial properties, most notably potent immunomodulation via their secretory factors that render them as an attractive cell source for cell therapy. However, their clinical application remains limited due to their low survival and persistence *in vivo*, highlighting the need for new cell-carriers¹. Chitosan is a widely applied biomaterial, but its poor solubility has constrained its use as a cell carrier². We examined the fabrication of chitosan-based MSCs-microcarriers using a water-soluble chitosan lactate (ChLA) derivative and *in situ* crosslinking in a microfluidic device using tripolyphosphate (TPP) and glycerylphytate (G₁Phy) as ionic crosslinkers. G₁Phy is a powerful antioxidant,³ whose crosslinking ability has been evinced⁴. Our microgel synthesis allows for cell encapsulation, and G₁Phy provided beneficial features to microgels in terms of MSCs survival, persistence and secretome modulation.


Experimental methods: ChLA microgels were synthesized by *in situ* crosslinking reaction in a microfluidic device (Fig. 1a). Two crosslinker compositions were analyzed: TPP:G₁Phy-microgels, and TPP-microgels, which did not contain G₁Phy. Cellular viability was assessed by live/dead assay. To evaluate the antioxidant effect of G₁Phy on MSCs, cells were cultured under oxidative stress and their secretome was analysed using a multiplex LUMINEX® assay. *In vivo* cell persistence and viability were studied by tracking microgels containing luciferase-transfected MSCs, subcutaneously injected in immunocompromised mice using an IVIS Spectrum CT.

Image:


a)




b)



c)



d)



	TPP	TPP:G ₁ Phy	hMSCs-only
Half life	1.553	3.927	
Decay rate	0.446	0.176	

Fig. 1: a) Microfluidic device and microgel synthesis approach; b) Cellular viability over time; c) Cytokine secretion of encapsulated MSCs under oxidative stress; d) Normalized bioluminescence flux (%) over time.

Table:

ChLA microgels were successfully synthesized through *in situ* crosslinking reaction in microfluidic devices. For both microgel compositions, our fabrication method allowed efficient cell encapsulation with over 70% cellular viability due to the use of: (i) water-soluble chitosan derivative; and (ii) biocompatible ionic crosslinkers with fast crosslinking kinetics. MSCs viability in TPP-microgels decreased up to 13±4% after 10 days of culture, while it remained stable (62±8%) for TPP:G₁Phy-microgels (Fig. 1b). This result indicates that G₁Phy maintained cell survival over time.

We observed an upregulated secretion of pro-survival and pro-angiogenic cytokines (Fig. 1c) for TPP:G₁Phy- in comparison to TPP-microgels under oxidative stress. Thus, the immunoregulatory effect of G₁Phy was demonstrated on injured-like tissue environment, which are characterized by a high concentration of oxidative species.

Benefits of G₁Phy were also demonstrated *in vivo*. Bioluminescence tracking showed higher half-life values for TPP:G₁Phy- than for TPP-microgels, indicating an enhanced cell persistence and survival (Figure 1d).

Results and discussions: ChLA microgels were successfully synthesized through *in situ* crosslinking reaction in microfluidic devices. For both microgel compositions, our fabrication method allowed efficient cell encapsulation with over 70% cellular viability due to the use of: (i) water-soluble chitosan derivative; and (ii) biocompatible ionic crosslinkers with fast crosslinking kinetics. MSCs viability in TPP-microgels decreased up to 13±4% after 10 days of culture, while it remained stable (62±8%) for TPP:G₁Phy-microgels (Fig. 1b). This result indicates that G₁Phy maintained cell survival over time.

We observed an upregulated secretion of pro-survival and pro-angiogenic cytokines (Fig. 1c) for TPP:G₁Phy- in comparison to TPP-microgels under oxidative stress. Thus, the immunoregulatory effect of G₁Phy was demonstrated on injured-like tissue environment, which are characterized by a high concentration of oxidative species.

Benefits of G₁Phy were also demonstrated *in vivo*. Bioluminescence tracking showed higher half-life values for TPP:G₁Phy- than for TPP-microgels, indicating an enhanced cell persistence and survival (Figure 1d).

Conclusions: Given all beneficial properties provided by G₁Phy, we envision that our G₁Phy-crosslinked ChLA microgels will have promising applications as MSCs-delivery platforms.

References/Acknowledgements: 1. G. Choe et al. *Polymers* 10(9), 2018
2. F. Croisier et al. *European Polymer Journal* 49(4), 2013
3. Ana Mora-Boza et al. *Scientific Reports* 9(1), 2019
4. Ana Mora-Boza et al. *Biomaterials Science*, 2020

Disclosure of Interest: None Declared

Keywords: Biopolymeric biomaterials, Hydrogels for TE applications, Stem cells and cell differentiation